1 Min Read
May 17 (Reuters) - Trovagene Inc:
* TROVAGENE ANNOUNCES COMPLETION OF FIRST DOSING COHORT OF PATIENTS IN ONGOING PHASE 1B/2 TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.